Moleculin Biotech Secures Hong Kong Patent Until 2040
Moleculin Biotech announced a significant advancement in its intellectual property portfolio with the issuance of a Hong Kong patent covering its proprietary method of reconstituting liposomal Annamycin. The newly granted patent extends protection through June 25, 2040, further reinforcing Moleculin's long-term global exclusivity strategy. The invention is jointly owned with The University of Texas System.
